HPMA copolymer-antibody constructs in neoplastic treatment: an overview of therapeutics, targeted diagnostics, and drug-free systems
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
32652110
DOI
10.1016/j.jconrel.2020.06.040
PII: S0168-3659(20)30375-8
Knihovny.cz E-resources
- Keywords
- APDC, Antibody, Drug-free therapeutics, HPMA copolymers, Targeting,
- MeSH
- Methacrylates * MeSH
- Nanomedicine MeSH
- Polymers MeSH
- Drug Delivery Systems * MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- hydroxypropyl methacrylate MeSH Browser
- Methacrylates * MeSH
- Polymers MeSH
In the past decades, nanosized drug delivery systems based on N-(2-hydroxypropyl)methacrylamide copolymers (pHPMA) have gained increasing attention in nanomedicine field due to their hydrophilicity, versatility, biocompatibility, non-toxicity, and non-immunogenicity. Indeed, pHPMA nanosystems with various controlled drug release capabilities inside targeted tissues or cells have been intensively studied. This paper summarizes recent advances in the design and application of pHPMA conjugates with specific antibodies or their fragments, focusing predominantly on the systems for the cancer therapy, particularly, the mechanisms of action of therapeutic antibodies, the approaches of their modification and subsequent attachment of pHPMA and their conjugates with diverse active moieties. Finally, we highlight the major biomedical applications of these antibody-polymer-drug conjugates and consider directions of possible development over the coming decade.
References provided by Crossref.org
Polymer-Antimicrobial Peptide Constructs with Tailored Drug-Release Behavior
HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery
Coating Persistent Luminescence Nanoparticles With Hydrophilic Polymers for in vivo Imaging